STUDYID,SUBJID,AGE,STR01,STR01N,STR01L,STR02,STR02N,STR02L,TRT01P,TRT01PN,PARAM,PARAMCD,AVAL,CNSR,CNSDTDSC,DCTREAS
PSIVISSIG0002,1,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,2,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1101,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,3,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1771,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,4,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,289,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,5,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,388,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,6,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1587,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,7,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,117,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,8,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1330,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,9,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1411,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,10,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,11,65,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,975,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,12,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,309,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,13,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,14,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1501,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,15,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,21,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,16,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,151,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,17,60,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,124,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,18,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,560,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,19,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,169,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,20,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,179,1,Censored at the last contact date,DEATH
PSIVISSIG0002,21,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,272,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,22,35,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1205,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,23,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1093,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,24,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,680,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,25,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,28,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,26,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,27,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,26,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,28,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,994,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,29,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,30,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,749,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,31,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,32,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,32,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,33,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,98,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,34,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,35,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,851,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,36,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1593,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,37,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,311,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,38,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,39,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,40,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,655,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,41,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,292,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,42,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,213,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,43,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,111,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,44,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,45,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,163,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,46,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,224,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,47,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,434,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,48,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,267,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,49,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,491,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,50,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,0,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,51,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,108,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,52,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,53,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,147,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,54,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,734,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,55,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,695,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,56,52,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,985,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,57,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,18,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,58,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,27,1,Censored at the last contact date,DEATH
PSIVISSIG0002,59,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,860,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,60,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,61,50,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1125,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,62,59,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,324,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,63,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,890,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,64,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,426,1,Censored at the last contact date,DEATH
PSIVISSIG0002,65,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,246,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,66,22,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1726,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,67,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,140,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,68,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,147,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,69,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1603,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,70,46,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,44,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,71,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,819,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,72,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,469,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,73,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,74,63,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,801,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,75,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1405,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,76,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,784,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,77,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,785,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,78,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,79,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1062,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,80,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,82,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,81,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,82,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,135,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,83,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,84,61,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1153,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,85,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,396,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,86,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1691,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,87,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1614,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,88,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,731,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,89,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,657,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,90,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,808,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,91,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,92,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,71,1,Censored at the last contact date,DEATH
PSIVISSIG0002,93,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1497,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,94,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,977,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,95,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,96,59,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,97,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,842,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,98,24,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,25,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,99,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,237,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,100,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,101,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1015,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,102,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,103,57,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,438,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,104,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1326,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,105,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1546,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,106,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,79,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,107,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,744,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,108,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1249,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,109,44,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,801,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,110,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1741,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,111,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,631,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,112,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,484,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,113,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,610,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,114,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,626,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,115,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,116,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,274,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,117,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,307,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,118,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1207,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,119,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,120,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,121,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,169,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,122,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1614,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,123,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1277,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,124,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,727,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,125,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,304,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,126,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1232,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,127,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1400,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,128,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,129,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,561,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,130,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,779,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,131,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1050,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,132,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,639,1,Censored at the last contact date,DEATH
PSIVISSIG0002,133,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,828,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,134,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,135,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,679,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,136,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,744,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,137,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,557,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,138,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,139,65,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,140,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1622,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,141,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1195,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,142,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,87,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,143,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,299,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,144,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,41,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,145,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,618,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,146,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,72,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,147,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,148,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,228,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,149,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,653,1,Censored at the last contact date,DEATH
PSIVISSIG0002,150,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,86,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,151,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,739,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,152,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,122,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,153,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,276,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,154,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1083,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,155,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,156,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,273,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,157,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,665,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,158,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,159,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,970,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,160,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,416,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,161,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,688,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,162,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1053,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,163,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1727,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,164,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,264,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,165,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,181,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,166,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,735,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,167,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,411,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,168,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,28,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,169,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,170,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,13,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,171,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,642,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,172,64,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,207,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,173,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,120,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,174,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,122,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,175,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1497,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,176,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1606,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,177,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,968,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,178,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,179,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,502,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,180,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,181,17,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,744,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,182,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1338,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,183,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,223,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,184,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1260,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,185,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1114,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,186,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,929,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,187,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1349,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,188,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,189,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,190,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,191,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,557,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,192,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,660,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,193,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,194,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,461,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,195,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,332,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,196,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,986,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,197,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1276,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,198,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1623,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,199,21,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,930,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,200,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,543,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,201,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1534,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,202,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,149,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,203,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,239,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,204,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,953,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,205,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,206,42,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,85,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,207,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,548,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,208,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,209,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1282,1,Censored at the last contact date,DEATH
PSIVISSIG0002,210,29,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,498,1,Censored at the last contact date,DEATH
PSIVISSIG0002,211,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,44,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,212,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1134,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,213,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,81,1,Censored at the last contact date,DEATH
PSIVISSIG0002,214,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,125,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,215,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,87,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,216,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,80,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,217,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1002,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,218,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,571,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,219,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,220,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,212,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,221,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1432,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,222,28,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,125,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,223,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,487,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,224,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1645,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,225,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,190,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,226,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,227,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,299,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,228,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,26,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,229,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1572,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,230,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,769,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,231,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,246,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,232,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1104,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,233,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,234,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,235,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,197,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,236,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,817,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,237,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,306,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,238,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,239,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,184,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,240,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,241,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1358,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,242,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,156,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,243,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,941,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,244,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,904,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,245,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,246,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,160,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,247,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,484,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,248,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,707,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,249,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,603,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,250,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,526,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,251,37,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,998,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,252,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,253,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1748,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,254,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,752,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,255,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,256,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,50,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,257,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,487,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,258,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,259,64,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,436,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,260,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,31,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,261,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,281,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,262,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,892,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,263,20,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1112,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,264,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,75,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,265,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,166,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,266,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,267,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1308,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,268,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,577,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,269,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,287,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,270,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,271,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,200,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,272,44,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,273,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,468,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,274,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,380,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,275,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1342,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,276,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,115,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,277,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,391,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,278,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,714,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,279,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,753,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,280,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,33,1,Censored at the last contact date,DEATH
PSIVISSIG0002,281,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,552,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,282,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,16,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,283,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,284,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,285,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,286,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,761,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,287,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1677,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,288,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,289,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,928,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,290,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1488,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,291,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,621,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,292,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,293,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,294,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,295,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,296,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,87,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,297,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,402,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,298,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,275,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,299,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,300,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,301,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,302,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,10,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,303,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1644,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,304,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,882,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,305,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,306,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,763,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,307,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1283,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,308,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,309,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,243,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,310,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,311,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,102,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,312,35,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,313,52,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,153,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,314,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,388,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,315,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,676,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,316,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,91,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,317,64,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,811,1,Censored at the last contact date,DEATH
PSIVISSIG0002,318,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,653,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,319,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,320,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,321,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,322,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,759,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,323,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,324,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1045,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,325,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,326,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,707,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,327,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,801,1,Censored at the last contact date,DEATH
PSIVISSIG0002,328,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,329,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,330,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,77,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,331,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,266,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,332,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,149,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,333,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,334,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,335,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,306,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,336,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,5,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,337,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,338,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,794,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,339,29,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1089,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,340,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,299,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,341,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,480,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,342,63,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1148,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,343,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,601,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,344,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,345,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,242,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,346,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1136,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,347,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,348,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,59,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,349,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,659,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,350,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,825,1,Censored at the last contact date,DEATH
PSIVISSIG0002,351,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1454,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,352,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,758,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,353,64,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1023,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,354,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,463,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,355,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,356,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,229,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,357,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,345,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,358,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,359,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,368,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,360,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1025,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,361,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,766,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,362,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,40,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,363,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1349,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,364,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,365,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,366,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,98,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,367,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,250,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,368,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,30,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,369,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,370,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1264,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,371,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,347,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,372,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,178,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,373,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,374,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,441,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,375,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,171,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,376,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,377,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,147,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,378,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,21,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,379,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,93,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,380,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,381,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,755,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,382,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,383,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1109,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,384,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,342,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,385,26,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,386,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,235,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,387,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,136,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,388,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,711,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,389,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,390,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,572,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,391,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,141,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,392,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1247,1,Censored at the last contact date,DEATH
PSIVISSIG0002,393,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,401,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,394,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,11,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,395,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,362,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,396,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1688,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,397,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,398,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1659,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,399,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1369,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,400,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,512,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,401,61,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,186,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,402,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,524,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,403,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,70,1,Censored at the last contact date,DEATH
PSIVISSIG0002,404,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,405,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1062,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,406,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,407,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1176,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,408,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,698,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,409,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1225,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,410,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,232,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,411,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1003,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,412,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,380,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,413,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,15,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,414,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,415,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,416,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,888,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,417,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,907,1,Censored at the last contact date,DEATH
PSIVISSIG0002,418,22,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1637,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,419,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,420,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,427,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,421,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,391,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,422,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1319,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,423,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,424,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,425,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,894,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,426,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,427,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,807,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,428,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,429,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,226,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,430,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,934,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,431,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,520,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,432,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,416,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,433,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,471,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,434,63,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,834,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,435,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,995,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,436,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,610,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,437,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,438,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,243,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,439,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,639,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,440,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,176,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,441,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,442,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,443,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,703,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,444,66,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,445,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,727,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,446,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,210,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,447,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1046,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,448,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,489,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,449,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,450,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,975,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,451,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1358,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,452,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,536,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,453,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1276,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,454,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1097,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,455,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,100,1,Censored at the last contact date,DEATH
PSIVISSIG0002,456,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,692,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,457,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,458,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,247,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,459,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,460,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,384,1,Censored at the last contact date,DEATH
PSIVISSIG0002,461,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1335,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,462,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1246,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,463,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,245,1,Censored at the last contact date,DEATH
PSIVISSIG0002,464,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,40,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,465,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,409,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,466,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,853,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,467,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,468,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,253,1,Censored at the last contact date,DEATH
PSIVISSIG0002,469,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,470,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,611,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,471,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1388,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,472,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,726,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,473,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,167,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,474,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1465,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,475,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,351,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,476,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1710,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,477,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1664,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,478,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,392,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,479,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,480,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,22,1,Censored at the last contact date,DEATH
PSIVISSIG0002,481,59,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,32,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,482,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,119,1,Censored at the last contact date,DEATH
PSIVISSIG0002,483,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,51,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,484,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,729,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,485,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,486,31,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,105,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,487,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,488,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,59,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,489,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1098,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,490,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,282,1,Censored at the last contact date,DEATH
PSIVISSIG0002,491,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,492,25,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,493,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,494,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,495,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,496,19,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,497,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,90,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,498,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,499,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1030,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,500,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1141,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,501,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,502,13,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,627,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,503,28,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1069,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,504,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1230,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,505,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,255,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,506,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,590,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,507,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,508,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1078,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,509,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,510,60,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,511,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,245,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,512,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,454,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,513,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,323,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,514,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,515,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,105,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,516,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,517,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,518,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,499,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,519,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,971,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,520,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1760,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,521,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,522,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,903,1,Censored at the last contact date,SUBJECT/GUARDIAN DECISION
PSIVISSIG0002,523,19,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,524,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,525,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,734,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,526,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,774,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,527,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,18,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,528,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,223,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,529,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,530,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1071,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,531,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,457,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,532,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,533,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,16,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,534,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,535,46,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,536,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,746,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,537,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,538,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1525,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,539,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,492,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,540,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,455,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,541,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,542,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,543,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,93,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,544,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,126,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,545,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,15,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,546,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,49,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,547,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,868,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,548,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,779,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,549,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,962,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,550,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1235,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,551,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,544,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,552,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,553,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,543,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,554,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,555,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,857,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,556,59,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,3,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,557,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1310,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,558,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,496,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,559,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,560,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,17,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,561,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,922,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,562,24,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,563,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,463,1,Censored at the last contact date,DEATH
PSIVISSIG0002,564,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,29,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,565,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,566,26,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,343,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,567,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,733,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,568,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,569,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,244,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,570,41,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,201,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,571,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,572,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,4,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,573,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,574,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,89,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,575,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,576,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,53,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,577,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,126,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,578,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,994,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,579,55,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,492,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,580,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,461,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,581,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,582,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,103,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,583,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,584,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,469,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,585,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1051,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,586,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1617,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,587,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,588,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,131,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,589,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,392,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,590,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,242,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,591,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,592,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,859,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,593,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,594,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1667,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,595,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,168,1,Censored at the last contact date,DEATH
PSIVISSIG0002,596,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,597,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,414,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,598,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,316,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,599,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,958,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,600,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,601,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,803,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,602,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,46,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,603,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,955,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,604,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,54,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,605,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,338,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,606,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1226,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,607,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,719,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,608,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,222,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,609,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,610,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,611,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,380,1,Censored at the last contact date,DEATH
PSIVISSIG0002,612,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1286,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,613,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,175,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,614,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1162,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,615,66,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1221,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,616,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,854,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,617,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1343,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,618,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,619,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,799,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,620,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,164,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,621,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,622,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,983,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,623,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,646,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,624,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,82,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,625,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1668,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,626,57,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,340,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,627,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,261,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,628,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,570,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,629,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,630,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,907,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,631,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,6,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,632,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,633,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1532,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,634,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,635,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,377,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,636,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,315,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,637,25,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,686,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,638,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,366,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,639,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,10,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,640,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,782,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,641,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,642,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,578,1,Censored at the last contact date,DEATH
PSIVISSIG0002,643,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,298,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,644,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,37,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,645,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,646,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,558,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,647,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,648,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,649,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,388,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,650,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1500,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,651,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,967,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,652,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,825,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,653,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,654,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1588,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,655,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,989,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,656,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,657,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,987,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,658,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1109,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,659,34,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,660,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1142,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,661,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,96,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,662,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1023,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,663,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,664,59,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,705,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,665,20,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,666,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,667,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,122,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,668,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,669,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1293,1,Censored at the last contact date,DEATH
PSIVISSIG0002,670,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,802,1,Censored at the last contact date,DEATH
PSIVISSIG0002,671,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,672,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,673,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1647,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,674,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,675,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,203,1,Censored at the last contact date,DEATH
PSIVISSIG0002,676,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,92,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,677,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,50,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,678,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,679,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,123,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,680,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,344,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,681,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,45,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,682,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,683,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,967,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,684,63,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1011,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,685,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,686,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1124,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,687,27,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,688,57,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,75,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,689,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,690,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1305,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,691,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1072,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,692,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1145,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,693,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,694,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1388,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,695,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1640,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,696,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,296,1,Censored at the last contact date,DEATH
PSIVISSIG0002,697,23,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,234,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,698,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1426,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,699,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,310,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,700,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,206,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,701,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,242,1,Censored at the last contact date,DEATH
PSIVISSIG0002,702,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,221,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,703,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,479,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,704,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1651,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,705,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1541,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,706,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1529,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,707,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,468,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,708,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,94,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,709,27,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1461,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,710,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,103,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,711,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1452,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,712,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,745,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,713,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,714,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,715,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,443,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,716,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,717,25,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1228,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,718,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,877,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,719,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,481,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,720,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,721,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,502,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,722,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,842,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,723,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,0,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,724,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,824,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,725,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,499,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,726,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,727,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,131,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,728,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1683,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,729,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,730,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,731,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,305,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,732,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,733,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,734,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,735,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1256,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,736,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,737,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,738,59,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,730,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,739,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,740,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,741,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,380,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,742,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,533,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,743,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,744,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,745,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,654,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,746,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,671,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,747,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,390,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,748,32,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,429,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,749,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,449,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,750,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,412,1,Censored at the last contact date,DEATH
PSIVISSIG0002,751,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,375,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,752,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,358,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,753,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,168,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,754,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,755,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,10,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,756,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,757,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,126,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,758,50,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1000,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,759,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,931,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,760,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,247,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,761,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,240,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,762,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,763,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,255,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,764,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,765,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,751,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,766,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,767,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,314,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,768,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,905,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,769,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,809,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,770,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,423,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,771,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,772,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,7,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,773,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,774,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,433,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,775,23,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,776,31,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,777,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,778,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,113,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,779,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1438,1,Censored at the last contact date,DEATH
PSIVISSIG0002,780,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,50,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,781,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,203,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,782,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,783,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,754,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,784,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,932,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,785,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,946,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,786,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1008,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,787,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,788,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,789,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1434,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,790,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1272,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,791,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,224,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,792,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,793,32,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1176,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,794,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,795,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1542,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,796,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,797,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1696,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,798,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,142,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,799,58,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,388,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,800,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,92,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,801,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,2,1,Censored at the last contact date,DEATH
PSIVISSIG0002,802,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,292,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,803,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,982,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,804,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,805,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,197,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,806,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1134,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,807,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,242,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,808,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,809,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,837,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,810,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1474,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,811,59,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1278,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,812,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,44,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,813,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,757,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,814,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,634,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,815,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1596,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,816,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,38,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,817,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,749,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,818,27,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,876,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,819,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,85,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,820,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,102,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,821,31,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,822,59,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1340,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,823,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,156,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,824,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,661,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,825,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,327,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,826,30,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,685,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,827,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,828,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1205,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,829,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,373,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,830,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,302,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,831,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,832,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1629,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,833,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,834,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,835,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,911,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,836,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,392,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,837,33,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,180,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,838,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,682,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,839,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,840,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,197,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,841,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,842,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,358,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,843,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,844,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,98,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,845,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1368,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,846,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,27,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,847,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,848,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,611,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,849,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,732,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,850,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,327,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,851,25,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,586,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,852,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1418,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,853,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1145,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,854,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,575,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,855,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,144,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,856,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1208,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,857,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,271,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,858,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,993,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,859,68,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1617,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,860,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,861,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,862,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,962,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,863,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,551,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,864,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,526,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,865,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,166,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,866,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,29,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,867,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,662,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,868,27,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,705,1,Censored at the last contact date,DEATH
PSIVISSIG0002,869,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,110,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,870,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,871,30,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1353,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,872,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1085,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,873,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1264,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,874,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,154,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,875,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,314,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,876,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1770,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,877,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,293,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,878,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,913,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,879,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,242,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,880,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1012,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,881,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,528,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,882,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,165,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,883,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,884,58,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,885,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,886,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,887,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,888,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,280,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,889,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1316,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,890,22,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1427,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,891,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,892,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,320,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,893,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,788,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,894,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,372,1,Censored at the last contact date,DEATH
PSIVISSIG0002,895,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,676,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,896,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1561,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,897,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,110,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,898,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,160,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,899,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,900,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,14,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,901,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,218,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,902,41,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,314,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,903,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1232,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,904,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,342,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,905,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,446,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,906,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1075,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,907,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,957,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,908,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,90,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,909,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,44,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,910,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,918,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,911,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,38,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,912,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1568,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,913,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,91,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,914,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,168,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,915,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,916,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,558,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,917,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,662,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,918,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1315,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,919,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,23,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,920,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,102,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,921,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,922,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,964,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,923,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1331,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,924,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1614,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,925,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,841,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,926,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,22,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,927,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1186,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,928,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,464,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,929,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,82,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,930,36,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,20,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,931,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,932,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1703,1,Censored at the last contact date,DEATH
PSIVISSIG0002,933,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1185,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,934,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1287,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,935,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,936,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1513,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,937,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1712,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,938,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,939,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,306,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,940,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,95,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,941,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,911,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,942,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1514,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,943,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,784,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,944,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,377,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,945,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1015,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,946,37,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,355,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,947,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,948,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,219,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,949,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,761,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,950,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,722,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,951,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,952,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,41,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,953,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,671,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,954,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1270,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,955,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,956,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,359,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,957,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,347,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,958,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,71,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,959,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1482,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,960,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,928,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,961,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,266,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,962,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,640,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,963,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,938,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,964,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,965,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,875,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,966,60,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1496,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,967,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,613,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,968,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,404,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,969,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,970,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,971,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,972,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,973,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,944,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,974,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1434,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,975,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,976,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,853,1,Censored at the last contact date,DEATH
PSIVISSIG0002,977,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,456,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,978,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1373,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,979,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,980,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,693,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,981,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1032,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,982,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,343,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,983,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1117,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,984,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,985,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,986,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,716,1,Censored at the last contact date,DEATH
PSIVISSIG0002,987,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1162,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,988,68,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,133,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,989,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,737,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,990,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,991,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,70,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,992,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,867,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,993,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,368,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,994,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1378,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,995,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,587,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,996,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,352,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,997,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1374,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,998,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,26,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,999,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,329,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1000,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,1045,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1001,26,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1183,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1002,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,170,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1003,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,38,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1004,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab + vismab 52 weeks,4,Progression-free survival (days),PFS,761,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1005,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,517,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1006,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,9,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1007,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1008,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,66,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1009,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,1438,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1010,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,77,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1011,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,782,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1012,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,vismab x 52 weeks,2,Progression-free survival (days),PFS,918,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,236,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,2,54,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1745,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,3,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1126,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,4,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,410,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,5,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,6,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,671,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,7,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1331,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,8,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1005,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,9,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,561,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,10,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1718,1,Censored at the last contact date,DEATH
PSIVISSIG0002,11,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,400,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,12,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1635,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,13,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,357,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,14,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,880,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,15,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,628,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,16,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,17,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,692,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,18,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1230,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,19,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,417,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,20,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,31,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,21,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,22,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,263,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,23,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,24,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,958,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,25,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,26,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,384,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,27,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,505,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,28,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,906,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,29,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,18,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,30,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,70,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,31,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,69,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,32,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,33,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,277,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,34,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,866,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,35,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,36,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1238,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,37,60,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,268,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,38,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,39,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,40,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,556,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,41,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,238,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,42,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,206,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,43,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,44,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1174,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,45,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1178,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,46,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,9,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,47,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,48,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1263,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,49,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,242,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,50,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,721,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,51,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,52,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,169,1,Censored at the last contact date,DEATH
PSIVISSIG0002,53,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,792,1,Censored at the last contact date,DEATH
PSIVISSIG0002,54,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1338,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,55,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1014,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,56,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,385,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,57,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1057,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,58,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,59,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1741,1,Censored at the last contact date,DEATH
PSIVISSIG0002,60,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,265,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,61,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,62,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,636,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,63,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,123,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,64,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,65,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,66,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1564,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,67,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,376,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,68,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,69,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,70,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,198,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,71,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1550,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,72,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1751,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,73,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,906,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,74,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,551,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,75,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,76,56,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,77,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1112,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,78,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,12,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,79,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,80,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1505,1,Censored at the last contact date,DEATH
PSIVISSIG0002,81,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,46,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,82,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1457,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,83,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,371,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,84,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,85,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1342,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,86,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,431,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,87,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,486,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,88,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1568,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,89,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,493,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,90,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1593,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,91,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,92,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,114,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,93,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,812,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,94,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,95,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,328,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,96,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,97,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,116,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,98,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,82,1,Censored at the last contact date,DEATH
PSIVISSIG0002,99,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1087,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,100,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,699,1,Censored at the last contact date,DEATH
PSIVISSIG0002,101,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,193,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,102,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,27,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,103,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,563,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,104,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,105,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,39,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,106,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,334,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,107,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,108,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,13,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,109,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,110,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,84,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,111,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,112,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,45,1,Censored at the last contact date,DEATH
PSIVISSIG0002,113,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,42,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,114,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,115,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,85,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,116,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,927,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,117,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1328,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,118,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1223,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,119,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1210,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,120,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,178,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,121,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,646,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,122,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1445,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,123,37,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,124,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1016,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,125,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,422,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,126,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,308,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,127,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,128,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,129,58,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,773,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,130,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1566,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,131,66,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,457,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,132,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1349,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,133,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1729,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,134,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,135,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1314,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,136,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,169,1,Censored at the last contact date,DEATH
PSIVISSIG0002,137,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,575,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,138,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,72,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,139,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1054,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,140,60,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,45,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,141,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1282,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,142,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,300,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,143,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,574,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,144,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,282,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,145,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,146,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,147,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,327,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,148,46,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,246,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,149,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1069,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,150,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,80,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,151,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,69,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,152,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1225,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,153,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,858,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,154,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,592,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,155,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,156,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,157,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,158,55,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,159,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,612,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,160,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1323,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,161,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,660,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,162,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,149,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,163,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1000,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,164,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,165,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,914,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,166,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,999,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,167,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1013,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,168,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,278,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,169,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,660,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,170,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1132,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,171,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,917,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,172,28,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,646,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,173,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,174,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,330,1,Censored at the last contact date,DEATH
PSIVISSIG0002,175,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1154,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,176,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,177,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,309,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,178,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,179,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,180,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,261,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,181,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,79,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,182,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,88,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,183,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,184,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,383,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,185,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1708,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,186,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,187,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1271,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,188,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1162,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,189,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,875,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,190,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,191,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1410,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,192,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,512,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,193,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,393,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,194,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1622,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,195,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,493,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,196,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,892,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,197,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,198,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,314,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,199,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,693,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,200,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,201,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,18,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,202,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,203,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,43,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,204,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1581,1,Censored at the last contact date,DEATH
PSIVISSIG0002,205,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1378,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,206,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,188,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,207,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1002,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,208,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,445,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,209,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,107,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,210,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,360,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,211,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,212,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,835,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,213,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,25,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,214,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,275,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,215,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1225,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,216,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,217,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,218,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1272,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,219,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,48,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,220,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,446,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,221,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1739,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,222,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,554,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,223,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,224,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,225,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,648,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,226,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,227,27,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,228,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,2,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,229,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1663,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,230,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1351,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,231,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,232,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,517,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,233,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,234,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,260,1,Censored at the last contact date,DEATH
PSIVISSIG0002,235,58,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,236,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,237,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1182,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,238,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,275,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,239,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,321,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,240,50,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1383,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,241,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,559,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,242,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,162,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,243,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,244,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1295,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,245,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,180,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,246,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1479,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,247,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1110,1,Censored at the last contact date,DEATH
PSIVISSIG0002,248,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,269,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,249,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,32,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,250,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1309,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,251,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,135,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,252,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,497,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,253,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,530,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,254,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,255,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,256,59,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,707,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,257,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1759,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,258,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,306,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,259,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,322,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,260,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,591,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,261,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1482,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,262,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1768,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,263,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,556,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,264,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1663,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,265,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1077,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,266,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1079,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,267,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1065,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,268,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,148,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,269,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,562,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,270,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,58,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,271,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,500,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,272,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,273,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,139,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,274,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,275,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,276,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,484,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,277,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,278,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,279,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,993,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,280,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,146,1,Censored at the last contact date,DEATH
PSIVISSIG0002,281,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,282,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1174,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,283,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,284,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,8,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,285,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,286,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,287,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,288,32,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,701,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,289,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1239,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,290,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1459,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,291,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1084,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,292,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,327,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,293,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,196,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,294,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,448,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,295,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,543,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,296,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,297,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,827,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,298,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1228,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,299,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,48,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,300,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,825,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,301,20,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,875,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,302,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,200,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,303,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,241,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,304,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,966,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,305,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,314,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,306,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1067,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,307,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1511,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,308,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1668,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,309,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,310,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,685,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,311,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,312,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,107,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,313,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,448,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,314,64,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,292,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,315,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,316,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1697,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,317,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1479,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,318,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1474,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,319,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,116,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,320,30,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1319,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,321,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,322,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1195,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,323,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,313,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,324,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,968,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,325,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,326,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1558,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,327,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,181,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,328,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,830,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,329,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1035,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,330,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,393,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,331,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,806,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,332,24,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1518,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,333,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,101,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,334,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,335,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,426,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,336,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,34,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,337,29,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,195,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,338,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1682,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,339,34,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,346,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,340,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1762,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,341,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,842,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,342,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,329,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,343,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,344,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,898,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,345,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,346,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,500,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,347,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,160,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,348,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,176,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,349,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,954,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,350,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,579,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,351,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1666,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,352,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,890,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,353,33,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,230,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,354,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,526,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,355,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,747,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,356,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,994,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,357,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,260,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,358,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,392,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,359,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,461,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,360,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,13,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,361,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,362,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,858,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,363,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,364,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,670,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,365,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,31,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,366,61,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,283,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,367,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1001,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,368,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,369,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,343,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,370,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1115,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,371,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1017,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,372,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,293,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,373,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,374,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,945,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,375,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,376,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,2,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,377,58,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,675,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,378,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,271,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,379,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,161,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,380,36,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,56,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,381,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1003,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,382,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1415,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,383,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,177,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,384,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,119,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,385,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,108,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,386,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,905,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,387,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1350,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,388,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1636,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,389,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,178,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,390,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,74,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,391,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,899,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,392,35,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,382,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,393,31,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,109,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,394,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,406,1,Censored at the last contact date,DEATH
PSIVISSIG0002,395,31,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,75,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,396,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,539,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,397,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,93,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,398,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,158,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,399,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,400,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,830,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,401,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,83,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,402,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,232,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,403,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,366,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,404,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1257,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,405,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,795,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,406,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,533,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,407,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,782,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,408,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1214,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,409,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,410,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,254,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,411,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,490,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,412,69,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,184,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,413,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,414,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,760,1,Censored at the last contact date,DEATH
PSIVISSIG0002,415,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,416,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,773,1,Censored at the last contact date,DEATH
PSIVISSIG0002,417,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,418,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,419,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1065,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,420,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,44,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,421,41,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,422,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,423,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,142,1,Censored at the last contact date,DEATH
PSIVISSIG0002,424,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1728,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,425,56,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,56,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,426,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,115,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,427,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,163,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,428,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1294,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,429,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,659,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,430,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,96,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,431,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,432,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,18,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,433,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,357,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,434,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1535,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,435,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,152,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,436,77,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,90,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,437,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,827,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,438,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,439,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,281,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,440,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,441,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,64,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,442,31,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,14,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,443,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,927,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,444,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,445,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,351,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,446,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,437,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,447,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,498,1,Censored at the last contact date,DEATH
PSIVISSIG0002,448,38,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,239,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,449,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,749,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,450,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,331,1,Censored at the last contact date,DEATH
PSIVISSIG0002,451,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,421,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,452,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,453,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,960,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,454,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,28,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,455,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,456,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,457,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,831,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,458,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,459,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,606,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,460,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,982,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,461,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,859,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,462,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,12,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,463,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,807,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,464,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1043,1,Censored at the last contact date,DEATH
PSIVISSIG0002,465,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1371,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,466,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,372,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,467,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,52,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,468,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,496,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,469,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,446,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,470,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,708,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,471,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,741,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,472,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,47,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,473,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,127,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,474,48,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,335,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,475,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,919,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,476,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,633,1,Censored at the last contact date,DEATH
PSIVISSIG0002,477,23,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,478,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1162,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,479,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,801,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,480,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,847,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,481,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,166,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,482,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,483,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,761,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,484,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1676,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,485,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,154,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,486,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,487,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,464,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,488,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,786,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,489,56,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,330,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,490,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1051,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,491,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,397,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,492,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,93,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,493,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,427,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,494,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,114,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,495,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1448,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,496,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1195,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,497,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,34,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,498,61,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,178,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,499,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1626,1,Censored at the last contact date,DEATH
PSIVISSIG0002,500,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,964,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,501,23,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,502,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,91,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,503,33,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1441,1,Censored at the last contact date,DEATH
PSIVISSIG0002,504,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,502,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,505,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1434,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,506,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,483,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,507,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,197,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,508,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,567,1,Censored at the last contact date,DEATH
PSIVISSIG0002,509,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,113,1,Censored at the last contact date,DEATH
PSIVISSIG0002,510,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,817,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,511,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,113,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,512,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1654,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,513,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,713,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,514,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,515,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,516,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,329,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,517,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1552,1,Censored at the last contact date,DEATH
PSIVISSIG0002,518,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1245,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,519,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1517,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,520,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,521,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1624,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,522,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,125,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,523,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,275,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,524,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,354,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,525,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,526,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,527,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,669,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,528,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,453,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,529,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,530,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,143,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,531,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,459,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,532,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1369,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,533,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1308,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,534,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1518,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,535,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,83,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,536,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1528,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,537,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,538,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,539,52,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,568,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,540,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,299,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,541,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1635,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,542,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,264,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,543,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,88,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,544,60,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,235,1,Censored at the last contact date,DEATH
PSIVISSIG0002,545,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,886,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,546,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,547,54,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,147,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,548,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,485,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,549,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,550,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,551,31,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,28,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,552,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1637,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,553,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,644,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,554,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,232,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,555,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,491,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,556,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1162,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,557,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1210,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,558,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,292,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,559,58,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,570,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,560,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,67,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,561,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1543,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,562,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,668,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,563,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1502,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,564,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,93,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,565,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1052,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,566,50,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,567,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,400,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,568,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,688,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,569,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,61,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,570,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1770,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,571,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,162,1,Censored at the last contact date,DEATH
PSIVISSIG0002,572,44,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,225,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,573,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,207,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,574,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,412,1,Censored at the last contact date,DEATH
PSIVISSIG0002,575,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,332,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,576,29,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1401,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,577,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,214,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,578,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,429,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,579,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,669,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,580,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,657,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,581,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,582,60,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,77,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,583,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,280,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,584,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1278,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,585,58,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,406,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,586,33,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,587,50,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1330,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,588,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,20,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,589,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1295,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,590,60,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,578,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,591,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,258,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,592,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,340,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,593,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,25,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,594,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,240,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,595,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,772,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,596,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1362,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,597,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1632,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,598,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,435,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,599,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,600,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,20,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,601,39,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,49,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,602,21,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,313,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,603,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,604,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,605,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,117,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,606,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,431,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,607,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,686,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,608,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,609,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,609,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1666,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,610,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,623,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,611,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,244,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,612,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,613,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,242,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,614,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,400,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,615,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,154,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,616,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,396,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,617,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,618,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,89,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,619,28,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,268,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,620,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,69,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,621,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1144,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,622,24,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,629,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,623,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,556,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,624,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,233,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,625,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,626,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1714,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,627,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,628,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,629,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,63,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,630,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1160,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,631,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,785,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,632,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,852,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,633,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,634,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,738,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,635,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,440,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,636,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1674,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,637,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,573,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,638,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,639,67,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,416,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,640,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,131,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,641,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,642,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,55,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,643,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1141,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,644,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,645,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,646,36,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,647,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1707,1,Censored at the last contact date,DEATH
PSIVISSIG0002,648,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,323,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,649,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,439,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,650,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,40,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,651,64,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,818,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,652,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1525,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,653,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1171,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,654,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,655,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,704,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,656,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,868,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,657,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,832,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,658,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,189,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,659,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,423,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,660,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,175,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,661,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,288,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,662,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,663,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,150,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,664,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,220,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,665,27,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,666,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,716,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,667,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,49,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,668,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,718,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,669,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,466,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,670,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1498,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,671,59,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,266,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,672,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1645,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,673,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1387,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,674,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,586,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,675,40,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,671,1,Censored at the last contact date,DEATH
PSIVISSIG0002,676,56,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,94,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,677,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,901,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,678,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,322,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,679,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,998,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,680,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,278,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,681,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,982,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,682,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,112,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,683,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,684,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,708,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,685,40,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,686,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,673,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,687,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1200,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,688,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,456,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,689,54,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,37,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,690,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,691,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,957,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,692,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1494,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,693,47,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,16,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,694,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,695,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,810,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,696,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,501,1,Censored at the last contact date,DEATH
PSIVISSIG0002,697,49,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,278,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,698,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,10,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,699,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,591,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,700,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,67,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,701,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,935,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,702,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,874,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,703,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1096,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,704,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,416,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,705,30,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,903,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,706,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1709,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,707,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,708,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1273,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,709,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,658,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,710,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,136,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,711,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,179,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,712,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,713,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,49,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,714,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,415,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,715,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,438,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,716,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,400,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,717,37,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,856,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,718,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,719,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,477,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,720,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,721,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1214,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,722,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1142,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,723,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,430,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,724,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,267,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,725,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,295,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,726,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,429,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,727,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,134,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,728,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,729,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1343,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,730,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1305,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,731,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,67,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,732,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,24,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,733,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,734,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,735,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,736,28,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,737,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1197,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,738,34,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,739,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,2,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,740,37,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1105,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,741,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,742,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1246,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,743,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,212,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,744,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,745,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,598,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,746,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1454,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,747,26,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,748,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,347,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,749,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,35,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,750,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,42,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,751,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,85,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,752,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,173,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,753,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1408,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,754,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,634,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,755,55,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,756,57,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,757,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,391,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,758,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,759,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,760,65,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,761,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,146,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,762,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1143,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,763,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,214,1,Censored at the last contact date,DEATH
PSIVISSIG0002,764,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,765,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1269,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,766,25,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,28,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,767,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,768,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1616,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,769,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,555,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,770,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,771,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,772,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,366,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,773,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,12,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,774,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1551,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,775,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,109,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,776,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,900,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,777,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,238,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,778,31,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,48,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,779,38,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,330,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,780,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,753,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,781,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,582,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,782,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,783,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1270,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,784,62,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,132,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,785,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,459,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,786,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,787,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,567,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,788,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,104,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,789,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,108,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,790,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,443,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,791,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,792,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,557,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,793,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1235,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,794,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1414,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,795,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,663,1,Censored at the last contact date,DEATH
PSIVISSIG0002,796,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1658,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,797,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,620,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,798,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1730,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,799,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,93,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,800,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,801,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,54,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,802,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,805,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,803,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,99,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,804,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,805,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,476,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,806,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,340,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,807,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,808,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1187,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,809,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,218,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,810,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,899,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,811,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1412,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,812,52,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,813,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,58,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,814,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,815,52,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,108,1,Censored at the last contact date,DEATH
PSIVISSIG0002,816,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,320,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,817,63,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,277,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,818,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,727,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,819,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,820,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,510,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,821,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,822,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,151,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,823,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,531,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,824,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1221,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,825,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,464,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,826,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,442,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,827,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1231,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,828,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,56,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,829,35,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,830,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1158,1,Censored at the last contact date,DEATH
PSIVISSIG0002,831,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,174,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,832,48,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,251,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,833,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,335,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,834,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1728,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,835,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,450,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,836,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,16,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,837,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,638,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,838,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1354,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,839,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,358,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,840,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,266,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,841,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,509,1,Censored at the last contact date,DEATH
PSIVISSIG0002,842,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,450,1,Censored at the last contact date,DEATH
PSIVISSIG0002,843,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,258,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,844,29,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,865,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,845,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1362,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,846,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,703,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,847,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,515,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,848,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,89,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,849,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,267,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,850,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,154,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,851,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,144,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,852,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,587,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,853,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,405,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,854,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,896,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,855,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1070,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,856,64,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,857,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,370,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,858,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1642,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,859,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,61,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,860,59,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,644,1,Censored at the last contact date,DEATH
PSIVISSIG0002,861,26,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,862,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,361,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,863,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1061,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,864,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,188,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,865,27,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,478,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,866,42,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,388,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,867,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,952,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,868,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,585,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,869,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,348,1,Censored at the last contact date,DEATH
PSIVISSIG0002,870,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,871,29,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,235,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,872,33,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,619,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,873,61,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,874,58,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,273,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,875,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,624,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,876,29,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,877,42,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,62,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,878,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,660,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,879,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1097,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,880,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,881,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,82,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,882,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1389,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,883,62,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,343,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,884,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1419,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,885,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,38,1,Censored at the last contact date,DEATH
PSIVISSIG0002,886,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,51,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,887,45,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,927,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,888,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,796,1,Censored at the last contact date,DEATH
PSIVISSIG0002,889,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1562,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,890,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,928,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,891,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1611,1,Censored at the last contact date,DEATH
PSIVISSIG0002,892,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1067,1,Censored at the last contact date,DEATH
PSIVISSIG0002,893,42,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,894,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,383,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,895,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,788,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,896,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1067,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,897,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,969,1,Censored at the last contact date,DEATH
PSIVISSIG0002,898,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,899,61,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,50,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,900,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,901,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,902,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,459,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,903,37,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,568,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,904,47,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,566,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,905,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1137,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,906,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1586,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,907,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,535,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,908,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,187,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,909,34,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,710,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,910,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,864,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,911,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,314,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,912,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1574,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,913,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,914,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,145,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,915,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1421,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,916,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,369,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,917,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,232,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,918,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,117,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,919,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,255,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,920,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,598,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,921,40,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,894,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,922,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,201,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,923,48,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,924,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1152,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,925,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,692,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,926,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,927,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,690,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,928,37,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1166,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,929,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,433,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,930,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,647,1,Censored at the last contact date,DEATH
PSIVISSIG0002,931,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1027,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,932,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,348,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,933,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,935,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,934,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,292,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,935,34,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,872,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,936,50,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1058,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,937,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1486,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,938,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,965,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,939,28,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1349,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,940,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1244,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,941,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,942,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1115,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,943,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,944,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,186,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,945,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,441,1,Censored at the last contact date,DEATH
PSIVISSIG0002,946,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,947,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1679,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,948,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,93,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,949,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1534,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,950,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,951,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,325,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,952,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,758,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,953,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,954,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,955,56,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,22,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,956,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1036,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,957,45,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1406,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,958,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,395,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,959,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1541,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,960,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,961,30,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,553,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,962,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1145,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,963,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,995,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,964,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,965,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,301,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,966,60,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,268,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,967,56,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,459,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,968,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1064,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,969,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,377,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,970,41,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,76,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,971,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,134,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,972,42,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1138,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,973,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,535,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,974,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1310,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,975,56,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,425,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,976,39,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,977,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,108,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,978,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,225,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,979,53,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,88,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,980,49,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,944,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,981,54,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,697,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,982,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,437,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,983,46,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,984,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,985,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,904,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,986,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,985,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,987,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,422,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,988,44,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,255,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,989,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,990,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,827,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,991,52,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,518,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,992,55,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1076,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,993,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,42,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,994,41,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,995,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,113,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,996,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1056,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,997,32,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,991,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,998,43,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,12,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,999,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,389,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1000,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1490,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1001,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,275,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1002,32,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,537,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1003,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,231,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1004,41,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,520,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1005,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,160,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1006,51,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1007,44,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,303,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1008,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1009,52,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,985,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1010,36,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1085,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1011,23,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1175,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1012,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,362,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1013,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,483,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1014,29,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,235,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1015,37,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,468,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1016,50,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1521,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1017,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1018,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1058,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1019,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,274,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1020,49,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,44,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1021,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1022,43,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1023,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,925,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1024,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,573,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1025,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,435,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1026,51,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,495,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1027,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,472,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1028,24,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,692,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1029,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,392,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1030,44,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1338,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1031,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1530,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1032,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,453,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1033,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1732,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1034,30,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,672,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1035,32,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,252,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1036,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,235,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1037,35,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,795,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1038,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1660,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1039,53,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1217,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1040,34,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,383,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1041,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1042,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,350,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1043,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,16,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1044,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,391,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1045,42,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,103,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1046,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,63,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1047,39,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1048,39,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,369,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1049,30,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,822,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1050,57,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1047,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1051,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,156,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1052,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,587,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1053,49,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,105,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1054,46,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1328,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1055,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,864,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1056,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1057,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1058,38,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1059,38,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,722,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1060,53,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,333,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1061,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,604,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1062,55,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1676,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1063,43,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,92,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1064,51,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,145,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1065,47,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,170,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1066,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,851,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1067,45,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1068,46,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,879,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1069,50,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,227,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1070,47,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,240,1,Censored at the last contact date,DEATH
PSIVISSIG0002,1071,33,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,880,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1072,54,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,183,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1073,31,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,211,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1074,42,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1750,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1075,40,Positive,1,Hormone receptor positive,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,12,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1076,40,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1077,40,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,897,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1078,35,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,657,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1079,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,376,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1080,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1776,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1081,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,622,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1082,33,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1436,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1083,45,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1271,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1084,43,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1085,48,Positive,1,Hormone receptor positive,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,448,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1086,52,Negative,2,Hormone receptor negative,No,1,No prior radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1597,1,Censored at the last contact date,PROGRESSIVE DISEASE
PSIVISSIG0002,1087,36,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,1780,0,NA,
PSIVISSIG0002,1088,48,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 52 weeks,1,Progression-free survival (days),PFS,230,1,Censored at the last contact date,ADVERSE EVENT
PSIVISSIG0002,1089,51,Negative,2,Hormone receptor negative,Yes,2,Prior Radiotherapy,tablemab x 12 week -> vismab 34 weeks,3,Progression-free survival (days),PFS,1780,0,NA,
